Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

;All manufacturing costs for KRYSTEXXA after FDA approval are recorded as inventory as opposed to research and development prior to approval.

Selling, general and administrative expenses increased $15.0 million to $22.3 million for the three months ended September 30, 2011, from $7.3 million for the three months ended September 30, 2010.  The higher expenses for the three months ended September 30, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.  

Interest expense on the Company's convertible notes was $3.4 million for the three months ended September 30, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.  To participate by telephone, please dial:Domestic:

866-393-9370 International:

706-679-1207 Conference ID:

17722127The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary. A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing:Domestic:

855-859-2056 or 800-585-8367 International:

404-537-3406 Conference ID:

17722127ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Moun
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the ... that its " Easy Blog " - has received more than ...   "We are thrilled that so many people are ... , CEO of Easy Breathe. "We,re committed to making sleep apnea ... Blog to stay informed about sleep apnea news , ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19
... , , , OSAKA, Japan, ... announced today positive results from PEARL 2 - a ... In this trial, both lurasidone 40 and 120 mg/day were significantly more ... an overall discontinuation rate that was similar to placebo. , , ...
... , , , ... CXM ) today announced that all patients enrolled in the Company,s ... and that it plans to provide detailed safety and efficacy data ... http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase 2b MATRIX ...
Cached Medicine Technology:Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 2Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 3Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 4Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8
(Date:8/20/2014)... 20, 2014 The Workgroup for ... authority on the use of health IT to ... full agenda for its annual fall conference, WEDI-Con ... WEDI-Con 2014 will take place at the HYATT ... attracting a diverse cross-section of payers, providers, government ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 Online Health ... 2015. , According to Zane Benefits, with open enrollment ... are encouraged to start thinking about their healthcare needs. ... enrollment period will run from November 15, 2014 to ... purchase a new individual health insurance policy, or switch ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Attendees ... get a sneak peak at Los Angeles’ first multi-faceted ... a tour of a blossoming 1.5-acre high school campus ... a shipping container farm in the L.A. Art District. ... diversity of sustainable urban agriculture, will kick off Seedstock’s ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3
... and treated in many cases, say US doctors. In peripheral ... become blocked with the same kind of fatty deposits - ... of treating it is very simple - keep walking. While ... the ability to walk with ease. Positive effects are seen ...
... Nearly half of people with Parkinson's disease are using one ... as vitamins, message or acupuncture. Researchers at Johns Hopkins University ... than 200 people with Parkinson's disease. Forty per cent use ... cent use five or more different ones. There's no link ...
... Bubonic plague, the bacterium blamed for the Black Death ... biological weapon, has had its entire genome sequenced. The ... and picking up new genes from other microbes. ,That ... emerge. More ominously, it suggests that enhanced strains might ...
... with a skin condition called contact dermatitis may benefit from ... tomatoes, according to the results of a small study.// Individuals ... they come in contact with substances they are allergic to. ... the skin, and many people may not realize foods can ...
... New research confirms that the main ingredient in the -- ... loss when used long term. The younger you are when ... bone-related problems later in life. // ... our bone mass is constantly breaking down and re-building, usually ...
... Suppression of testosterone levels in men with testicular ... disease, warn US researchers.,A research team from North ... levels go down, a high rise in levels ... disease – occurs. They suggest that this phenomenon ...
Cached Medicine News:Health News:Sequencing of the Plague 2
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
... Greenspec Laryngoscopes are a high quality fiberoptic ... bringing greater standardization to fiberoptic laryngoscopes. The ... and indicates it's ability to interconnect with ... light offers a cool, bright and focused ...
... steel. Lamp supplied with blade. Oxygen ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
Medicine Products: